Monopar Therapeutics

Historical price data

Monopar Therapeutics is a clinical-stage biopharmaceutical company with a dual-pillar strategy focused on developing novel radiopharmaceuticals for oncology and a late-stage therapy for Wilson Disease. Its key achievement is the in-licensing of ALXN1840, which successfully met its primary endpoint in a Phase 3 trial, positioning it as a potential new standard of care. The company employs a capital-efficient, virtual operating model, drawing on a leadership team with a proven track record in rare disease drug development and commercialization to de-risk and accelerate its pipeline.

Asset-centric development focusing on a uPAR-targeted multi-isotope radiopharmaceutical theranostic platform for oncology and a novel, tissue-targeted copper chelation technology for Wilson Disease.

In Wilson Disease, ALXN1840 competes primarily against generic standard-of-care therapies, against which it has demonstrated superior efficacy. In radiopharmaceuticals, competition is broader and includes large pharma players, though Monopar is a first-mover with its specific uPAR-targeted theranostic approach.